🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
92.49
+0.54 (0.59%)
At close: Nov 18, 2026, 4:00 PM EST
92.60
+0.11 (0.12%)
After-hours: Nov 18, 2026, 4:32 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

2026 revenue guidance is $715M-$720M, with cash-flow-positive guidance for 2027 and significant contributions expected from ATEBRIOZ. Pipeline milestones include a brelovitug filing next year and volixibat data in PBC in Q1 2027.

Speaker 1

Welcome everyone to the next session here. Happy to be joined by Mirum Pharmaceuticals. We have CFO Eric Bjerkholt and Andrew McKibben, SVP Strategic Finance and IR. A lot going on at Mirum, so we can jump right in. Maybe, Eric or Andrew, if you just want to kind of give a brief overview of recent quarter. You've had a lot of data going on, so maybe just kind of set the stage, and then we can dive in.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

Sure. First, thank you for having us. Thank you to Stifel for organizing the conference. We will be making forward-looking statements, so please refer to risk factors in our SEC filings. We now have four approved medicines. We're experiencing really rapid revenue growth. We've guided to revenues of $715 million-$720 million for this year, with strong momentum going into next year. We see growth from all our medicines, and next year we expect significant contributions from ATEBRIOZ in FOP, which was very recently approved. We've guided to being cash flow positive in 2027. We were cash flow positive last year, cash flow positive first half of this year, but second half of this year, we have a heavy R&D lift in part with significant investments in CMC for the expected filing of brelovitug next year, as well as for volixibat.

Sets us up really well for continued growth and good financial performance next year.

Speaker 1

Great. Makes sense. Maybe we can just start off with some of the pipeline assets. Obviously, you guys have had kind of a lot of updates recently. I think PSC naturally remains kind of a focus for folks, so maybe it'd be helpful just to kind of lay out sort of some of the context there and sort of your kind of continued perspectives on sort of the path forward there.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

It's Andrew's favorite topic.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

Yeah. Yeah, you know, it's funny, no one asks us about this.

Thank you. Yeah, just a little bit of context. We're planning to file in the first half of next year. We received feedback in July from the FDA at our pre-NDA meeting. They recommended a phase III, but noted that we could file at our discretion. Based on our understanding of where that review team was, and it was a new review team, we felt that it would behoove us to take some turns to interact with them with our breakthrough designation before we put that submission in, just to bring them closer to the dataset. There was no specific issue that they were pointing at behind their recommendation or specific recommendations around what a phase III should look like, which tells us that there was just lack of familiarity with the program and a review team that was a bit newer to the program.

Taking a couple iterations to interact and get them closer to what we've done, it's a very robust data package, before we put that submission in, we thought would be prudent. That's where we are. If anything changes in this kind of back and forth with them between now and submission that's material, that changes our plans, we would certainly update you. But right now, everything's on track.

Speaker 1

Sounds good. You may not be able to answer this, but want to ask it. Just in terms of, do you think there is like sort of an alignment that is going to happen before you submit, or is it going to be more like we will just have to kind of see throughout the review? Just curious if you think there is going to-

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

The latter is a win, right?

Speaker 1

Yeah.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

I mean, rarely do I would not expect them to say, "I am sorry, we love you, please submit. Like, that just does not That is not a thing the FDA does. It is usually moving the conversation to a review issue, which is where we think a lot of this should be.

Speaker 1

Yeah. Makes sense. At AASLD this past weekend, you guys shared some additional data for PSC. Maybe just kind of recap that briefly and the importance of that data and rounding out the broader clinical profile for volixibat.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

Yeah, it goes back to the start of the program. I mean, as you know, there's a high degree of IBD in PSC patients. Around 70% have IBD. Going into the program, we were concerned that there's some potential for IBD exacerbation. We discussed that with the FDA. What we see is there's not. It's a pre-planned analysis from the get-go, giving us reassurance that there's going to be no exacerbation in PSC patients with IBD. So really, really reassuring.

Speaker 1

Yeah. Yeah. Makes sense. Maybe just while we're on PSC, totally understand, totally get your confidence going forward. On the regulatory front, maybe on just commercial, remind us the right way to think about that opportunity, how many patients are out there, and how many you think are truly addressable in terms of this addressing itch.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

For PSC, we believe there are about 50,000 patients in the U.S. About 60%, we believe, have a significant itch that would warrant treatment. So that is a very significant patient population. Probably a similar number outside of the U.S.

Really excited about what this could mean for us.

Speaker 1

Okay. Sounds good. I will talk about PBC in a little bit. Obviously, a lot has been going on in the HDV space as well recently. Maybe just kind of recap some of the data from AZURE-1. You just had AZURE-4 as well. I think you presented some longer-term data recently as well. So maybe just kind of set the stage with all that has happened.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

I mean, a lot of really exciting data coming out of the brelovitug program. So just to recap, AZURE-1 and AZURE-4, the two phase III studies that will form the basis of our BLA submission. Both of those studies met the primary endpoint, which we looked at 24 weeks, looking at treatment versus delayed therapy. So very clear signal very early on. You are getting really nice rapid viral suppression and normalization of ALT. I think taking a step back and looking at the full picture of data that we presented at AASLD over the weekend, what we also showed was those responses continue to deepen meaningfully over time, which is as expected. 24 weeks is enough to see a signal and support a filing, but we are tracking these patients out to 96 weeks.

The longest-term data that we presented, I think, is the most exciting, where at up to 108 weeks, and this is data from our phase IIa extension, you are seeing 100% ALT normalization, 100% virologic response, greater than 70% rates of TND, which is, I think, ultimately a nice objective to shoot for, but from a clinical and outcomes perspective, not that differentiated from the primary endpoint that we are looking at. Overall, I think it is a great profile, well-tolerated too, which was nice to see that confirmed in all these datasets.

Speaker 1

Yeah. No, totally makes sense. Just sort of on that point, there is a lot of different endpoints here, different virologic response sort of endpoints, assays. For docs, maybe just help us understand in the real world, what matters most, as it relates to sort of thinking about how docs will view sort of these different efficacy measures. What do you think is most important?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

Yeah, I mean, it is a really good point. I think it is easy to kind of get lost in the nuances of assays and different sensitivities. I mean, ultimately, what you are seeing with these antibody approaches and siRNA approaches is you are getting virus down to almost negligible levels, and that is what is important. I mean, this is a very progressive disease, so getting the virus under control and normalizing that liver inflammation are kind of the two main objectives you would look for in a treatment. When you talk to physicians, I think there is a lot of interest in potential for finite therapy and a cure, and I think that is the right objective for any kind of viral disease, is curing it. It will take some time for us to see if that is achievable here.

Ultimately, the current recommendations are to get to TND, which is the lowest level of viral load we are able to measure, and ALT normalization, and maintain that for 96 weeks or so before even experimenting with withdrawal. Part of the reason is that what we know about TND is that you can have it for some time, and then if you withdraw therapy, the virus rebounds. So TND is not elimination, it is just the lowest level of objectively virus we can measure, or in this case, cannot measure with the assays.

Speaker 1

Yeah. Yeah, makes sense. I think naturally, obviously, Vir had their data this weekend as well, and people are trying to draw comparisons between the two datasets from an efficacy perspective. Obviously, some differences in terms of timelines, patient populations are slightly different. I think the assays are slightly different. Maybe just help us understand the caveats in trying to draw direct comparison between the two datasets.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

I think it is important to draw back up to the big picture, which is that we are likely to have two highly effective therapies that both get approved and that both companies out there will develop what is likely to be a very significant opportunity to help thousands of patients with a significant unmet need. There is many situations where it helps to have several companies out there develop a new market. This is definitely going to be one of those patient-finding situations where we need to improve the levels of reflex testing that is going to help identify many more hepatitis B patients that have hepatitis D. Some patients might do better on our drug. We think we have some very significant advantages, and other physicians might prefer to prescribe the Vir drug, but I think we are going to be very successful here.

Speaker 1

Yeah. Makes sense. I think one thing with that study, there was a cap around the baseline ALTs. Can you maybe just help us understand what proportion of your study may have been excluded from that Vir study?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

About 20%, yeah.

Speaker 1

20%? Okay.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

I mean, I think there's notable differences on baseline ALT and baseline viral load. Viral loads are measured in a log scale, and when you're looking at those numbers, sometimes it doesn't look like there's a big difference, but comparing a 6.1 log to a 5.4 log on an absolute terms is a 4x difference in viral load, and we see our patients in our studies starting substantially higher. There's that to take into account too.

Speaker 1

Yeah. Makes sense. Obviously, we've talked a lot about efficacy. From a safety perspective, maybe just kind of help us understand how important that is in terms of treatment decisions in the real world, as it relates to things like flu-like symptoms and some of the other kind of safety dynamics in this space. Just curious how important that is relative to some of these efficacy nuances.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

We think it's important. I mean, we know how a patient feels matters, and we live that with LIVMARLI and see that with volixibat. I think that will come into part of the decision-making. We have pretty low rates of flu-like symptoms and a really nice tolerability profile, so that may matter for some.

Speaker 1

Mm-hmm. Yeah. Okay. Maybe just in the context of the commercial opportunity. I think there's just some inherent or some skepticism on this market in general, not even as it relates to kind of the competitive dynamics here. I think you guys point to 15,000 patients that are addressable in the sense of being diagnosed, under care, et cetera. Maybe just sort of walk us through kind of how you kind of arrived at that sort of epi number. Again, just sort of your confidence in that being like an addressable patient population kind of like relatively quickly.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

Yeah. So that's looking at claims data, and by doing that, we found 15,000 patients or so that are diagnosed with insurance and under care of a physician. We think that's a pretty solid number that forms kind of a baseline or a minimum, if you want. We do think that today, a very small portion of hepatitis B patients are being tested for hepatitis delta, and that once testing becomes more common which is likely to happen or will happen now that there's one, but soon to be, I think, three approved medicines that is going to change. A good example is what happened in Europe, where before the Gilead drug, Hepcludex, was approved, they were doing risk-based testing, which is generally what is happening here as well. But with the approval of Hepcludex, they started doing more reflex testing and ended up finding many, many more patients.

We think the same dynamic is going to happen here. Is it 2%, 3%, 4% of hepatitis B patients? We do not know, but that is probably about 2 million or so hepatitis B patients in the U.S. So, you could easily see getting to a very meaningfully larger number than the 15,000 baseline.

Speaker 1

Yeah. You guys recently raised your guidance here to greater than $1 billion for brelovitug, I think, versus $750 million previously. Maybe just walk through what drove that change and some of the underlying assumptions that get you there.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

That was really, to be honest, entirely driven by the fact that Hepcludex was priced more highly than what we had assumed when we put out the $750 million. So that difference just drives us to $1+ billion . But, as often is the case with us, we over time lean more to the plus than the than the base number. We'll see.

Speaker 1

Yeah. Makes sense. I presume you have competitive assumptions in sort of that billion-dollar guide as it relates to not just Vir, but also Gilead.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

Yeah, absolutely. I mean, we'll see how it plays out. I do think that between us and Vir, we're going to dominate this market. Exactly how the market shares split ends up is way too early to speculate on.

Speaker 1

Yeah. Makes sense. Maybe just, Gilead's been launched for a little bit now. Is there any sort of like insights you guys have on kind of that initial launch and this market or any key learnings?

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

I think it is too early and it looks like it is not a very high priority for them, but let us see how the next few quarters play out.

Speaker 1

Yeah. Maybe just like help us remind what that drug has done ex-U.S. in terms of like a revenue number, just to like put some context around what this opportunity may look like.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

Yeah. I mean, I think four years into the launch, they were at about a $200 million run rate ex-U.S. So it just points to how meaningful the opportunity is. That is obviously at a price level that is far below what the U.S. price would be.

Speaker 1

Yeah. Makes sense. Great. Anything else on HDV to specifically highlight or any specific questions on HDV?

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

I think we have covered it.

Speaker 1

Sounds good. Back to volixibat. We have PBC coming in 1Q 2027. Maybe just in the context of some of the PSC updates, if you could just kind of like lay out your confidence and sort of your alignment on that study. Obviously, we saw GSK's drug get approved on pruritus, but just curious your confidence, what you can sort of share in terms of your like alignment there on PBC.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

Yeah. We had interim data in 2024, a really nice signal, like over 2-point improvement in pruritus and improvements in sleep and fatigue. Based on that, we received breakthrough therapy designation from the FDA, which has allowed us more interaction and dialogue with them. So between then and now, there has been more communication around this program, the analysis plan. Feel much more confident in how they're viewing this and as viewing it as a pivotal study. I think there is a lot more precedent in PBC too. The design size approach is very much in line with other programs. So feeling pretty good about that.

Speaker 1

Makes sense. I think there is a general sort of investor view that that study has a high POS, obviously. Your interim, just the consistent kind of efficacy with this mechanism across these different etiologies. But, just sort of curious if you could kind of like lay out your perspectives and kind of what you're hoping to see there, and if there should be anything different versus what we saw in the interim.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

Anything in that ballpark. We saw, I think, a slightly over a 2-point placebo-adjusted itch benefit. I mean, it's a smaller population in the interim analysis. But anything there, I think, would be a win from our perspective. The competitive bar is, we think, relatively low. I think we're in a pretty good position here.

Speaker 1

Yeah, makes sense. I think there's some debate around the opportunity here, specifically in the context of the PPARs. Maybe what do you think investors are kind of missing as it relates to this commercial opportunity and how volixibat could be positioned within this treatment paradigm?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

It's a very large patient population, so 80,000 at least, possibly 100,000 patients. A 1/3 of those patients are well-controlled on UDCA but still have itch, and those patients are off-label for a PPAR. That 1/3 alone is a meaningful opportunity. Then you look into the patients that are sub-optimally controlled or not controlled, where the PPARs, you see most of the PPAR use. We expect share there as well. PPARs are not a universal, don't universally address itch. We have patients on PPARs in our study with moderate to severe pruritus. Ultimately, you don't need a large share of this population to make the opportunity meaningful, and we think we'll have a fantastic option.

Speaker 1

Yeah. Presumably, if the data are positive in 1Q, the review sort of timelines are probably going to be relatively similar for PBC and PSC with volixibat. Is that right?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

Well, after data, we'll still have to submit.

Speaker 1

Yeah.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

The PSC will be ahead and PBC will be following, but there may be some overlap.

Speaker 1

Yeah. In that context, how are you thinking about pricing with volixibat?

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

TBD.

Speaker 1

Yeah.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

We will have to look at the data, look at how the competitive dynamics evolve, but I mean, there is one line of thought that we would prioritize PSC, where we would be the only approved therapy. But that would probably lead to several step-throughs into the PBC opportunity, so we will have to give that a lot more thought and think very carefully about what the right approach is.

Speaker 1

Yeah. Makes sense. Great. Well, let us dive into the existing commercial business, LIVMARLI. Definitely want to talk about FOP quickly, but maybe just LIVMARLI, you have raised, and just kind of on your base business, you have raised guidance multiple times this year. It continues to go really well. What are really kind of the key growth drivers here? And as we look next year, the year beyond, where are we in terms of the kind of LIVMARLI launch? Is there at all a plateauing coming in terms of Alagille, PFIC and all the opportunity you have here?

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

No plateauing. Let us address that. So, we have two approved indication, Alagille and PFIC. Alagille is a steady grower, I would say. We probably slightly north of 50% penetrated of the opportunity, but we keep adding patients every quarter, every month, and there is also a weight-based dosing dynamic that is at play, so that is growing very nicely. But the main engine behind the rapid growth has been PFIC, both pediatric but also adult PFIC. We think there is at least 2,000 adult PFIC patients in the U.S., and so of those, a small minority are diagnosed today.

Very significant upside. To fully capitalize on that opportunity, we are expanding our sales force, both for adult PFIC but also for brelovitug and volixibat. We are adding about 40 reps. They should all be in place around year-end this year, and excited about having them in the field and seeing what they can do.

Speaker 1

Yeah. Kind of the PFIC experience to date thus far is kind of without that specific investment in sort of the adult sales force.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

We are probably only calling on the top decile of adult hepatologists at this point, so a lot of room to grow.

Speaker 1

Yeah. I think the other interesting thing that you guys have talked about in the past and has kind of been discussed in the community is genetic testing, and specifically in these adult hepatology clinics. Has that even really happened yet, and is that why we're finding more PFIC patients, or is that still down the road for that to come?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

It's early days. It's not something that we see gastros and heps very adult, on the adult side, very familiar with. Obviously, on the pediatric side, they do that all day. We are seeing growing interest and adoption. Obviously, that is something that we and Ipsen are doing to help facilitate.

Speaker 1

Yeah.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

We both sponsor genetic test panels. We think that that is helping, and you are seeing more interest in genetics at the adult liver conferences as well. It is, I would say, early days. We are doing what we can to accelerate it.

Speaker 1

Yeah. 2,000 adult PFIC patients in the U.S., a small minority are diagnosed today. What do you think that number Do you think half those adults get diagnosed over the next five years, or just curious if you can kind of help us understand kind of the pace with which this market is going to be built over the coming years?

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

I think it's hard to quantify.

Speaker 1

Yeah.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

Don't really have an opinion on the pace, except that I think it's going to continue to grow. And it's actually an example of an opportunity where I think it helps to have two people out there developing the market. I think BYLVAY and LIVMARLI are both used to treat PFIC patients. We probably have about a 50/50 share. I think we both benefit from that dynamic.

Speaker 1

Yeah. Do you think it will kind of stay around that 50/50 over time?

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

Hopefully we can continue to do a great job. They've had a large sales force out there for a while, right?

Speaker 1

Yeah.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

We're just expanding our sales force, so maybe we can increase that over time.

Speaker 1

Yeah.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

We'll have to prove that.

Speaker 1

Yeah. No, makes sense. I think it's an interesting point you mentioned around not only the upside or opportunity with LIVMARLI, but the leverage you'll get as it relates to HDV, presumably PSC and PBC, as you kind of expand this adult sales force. So it's kind of across your whole portfolio. Is that the right way to think about it?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

Yeah.

Speaker 1

Great. Well, also with LIVMARLI recently, you had the EXPAND data that were positive. Maybe just help us understand if there's any specific labeling implications or regulatory implications, but more just sort of how big that opportunity can be.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

Yeah, I mean, it was really, really happy with that phase III readout. Very clear benefit in the overall population, and then the subset of biliary atresia patients, which represented about half of the study. TBD on what the label ends up looking like. I mean, that'll obviously be a conversation with the FDA. But the way we've talked about the opportunity is if you just look at biliary atresia alone, there are at least 1,000 addressable patients in the U.S., so that's with their native liver and pruritus. So that's comparable in size to Alagille. The dose is a bit higher, so it's about 1.5x the dose of the Alagille patient, but ultimately a comparable opportunity at a minimum. Then kind of think about the other bucket as upside to it.

Speaker 1

Mm-hmm. Ipsen failed their biliary atresia study, so there's no competition within sort of the biliary atresia setting. Makes total sense. In your study, about half of it, like you said, was biliary atresia. As it relates to the real world in terms of what the right way to think about the size of that tail of other cholestatic indications, is that sort of the right proxy as well in the real world?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

It's our best guess.

Speaker 1

Yeah.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

We had a study with multiple sites open for a little over a year, and we got half and half.

Speaker 1

Yeah. Okay. I guess in that, outside of biliary atresia, I know that study specifically was more focused around pediatrics, but do you think those other cholestatic diseases tend to be more like adult patients, or is it going to be more pediatrics?

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

No, there will be some. Yeah, I mean, this was a heavily focused pediatric study. But going back to the conversation around PFIC and diagnosing PFIC, you are looking at idiopathic cholestasis. We think about 20% of those patients have underlying PFIC genetics. That other 70%-80%, some of those could be EXPAND patients.

Speaker 1

Yeah. Makes sense. And I guess maybe, Eric, just seems like there are so many tailwinds here and still so much room for LIVMARLI. Is the Street and models kind of right over the coming years as it relates to what LIVMARLI can become, or do you think people are still missing what this ultimate opportunity is?

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

I think most Street models do not quite correctly appreciate the opportunity long- term, but maybe that is okay for now.

Speaker 1

Yeah. No, makes sense. Okay, maybe just last question quickly on LIVMARLI. I think just as more people have started to do a little bit more work, just given how well it's gone, IP has come up a little bit more recently. So maybe just kind of lay out your IP and just the confidence as it relates to kind of what the length of protection here may look like.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

Yeah, we feel very good about our dosing patents portfolio going out to 2040. We have also a solid dose patent going out to 2043. And those patents came from an insight that there's kind of a strange dosing mechanic in IBAT, and particularly with LIVMARLI, where it tends to plateau, and the efficacy plateaus, and you have to dose through that to get to the efficacy we're seeing. We think those patents were highly prosecuted and issued and are very solid.

Speaker 1

Mm-hmm. In terms of some of the Paragraph IV, is there any sort of timelines or catalysts as it relates to some of this IP stuff, or?

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

The next step is Markman hearing, which I think is around next summer, and then there'll be several years after that and before. Could take a while before this resolves.

Speaker 1

Yeah. Makes sense. Great. Maybe just in the last 20 seconds, FOP, I think it obviously gets or tends to get less attention relative to some of the other stuff you got going on. You got to greater than $200 million. Maybe just briefly kind of characterize how you think about that opportunity and the strength of the data that you've seen.

Eric Bjerkholt
CFO, Mirum Pharmaceuticals

Yeah, there's about 900 patients worldwide, at least 300, maybe a little bit more in the U.S. Highly engaged population diagnosed. This is not a patient-finding exercise. We're really encouraged by what we've seen in the first few weeks of the launch, and I have high expectations going forward.

Speaker 1

Great. Well, thanks both for being here, and thanks for everyone listening in.

Andrew McKibben
SVP of Strategic Finance and Investor Relations, Mirum Pharmaceuticals

Yeah. Thanks for having us.